West Pharma (WST) Tops Q2 EPS by 3c; Raises Outlook

West Pharma (NYSE: WST) reported Q2 EPS of $0.59, $0.03 better than the analyst estimate of $0.56. Revenue for the quarter came in at $388 million versus the consensus estimate of $384.58 million.

GUIDANCE:

West Pharma sees FY2016 EPS of $2.15-$2.25, versus prior guidance of $2.12-$2.25 and the consensus of $2.21. West Pharma sees FY2016 revenue of $1.505-1.52 billion, versus prior guidance of $1.49-1.51 billion and the consensus of $1.5 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Carnival shares drop despite earnings beat on weak guidance